Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer.

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death,

The Government’s plans for prostate cancer screening do not go far enough, experts have warned. James Murray, the new Health Secretary, accepted recommendations from advisers on Tuesday to restrict routine screening only to a few thousand men,

The health secretary has decided only a few thousand men at high risk of getting prostate cancer will be offered targeted screening for the disease.

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi

A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy.

The Health Secretary has confirmed that thousands more Black men will be invited to participate in a prostate cancer screening trial, as he reiterated his commitment to "following the science" by not endorsing population-wide testing.

A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has found that a combination prostate cancer treatment ...

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent combined with aglatimagene besadenovec (aglatimagene) plus valacyclovir compared to placebo plus valacyclovirFindings support that addition of aglatimagene to standard-of-care radiotherapy can provide a meaningful benefit without increasing clinically significant toxicity    Data reported in this publication will support planned Biologics License Application (BLA) submission for aglatimagene in fourth quarter of 2026 NEEDHAM,